These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 30296172)

  • 1. The use of estradiol metered-dose transdermal spray in clinical practice.
    Fait T; Fialova A; Pastor Z
    Climacteric; 2018 Dec; 21(6):549-553. PubMed ID: 30296172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of efficacy and local tolerability of estradiol metered-dose transdermal spray to estradiol patch in a network meta-analysis.
    Kovács G; Zelei T; Vokó Z
    Climacteric; 2016 Oct; 19(5):488-95. PubMed ID: 27593417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Transdermal estrogen spray in therapy of postmenopausal syndrome].
    Fait T
    Ceska Gynekol; 2016 Jan; 81(1):77-80. PubMed ID: 26982070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical usefulness of a low-dose maintenance therapy with transdermal estradiol gel in Japanese women with estrogen deficiency symptoms.
    Mizunuma H
    Climacteric; 2011 Oct; 14(5):581-9. PubMed ID: 21848497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter, open-label study to evaluate satisfaction and menopausal quality of life in women using transdermal estradiol/norethindrone acetate therapy for the management of menopausal signs and symptoms.
    Adler G; Young D; Galant R; Quinn L; Witchger MS; Maki KC
    Gynecol Obstet Invest; 2005; 59(4):212-9. PubMed ID: 15753617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of steady state development and reduction of menopausal symptoms after oral or transdermal delivery of 17-β-estradiol in young healthy symptomatic menopausal women.
    Rohr UD; Volko CD; Schindler AE
    Horm Mol Biol Clin Investig; 2014 Jun; 18(3):123-36. PubMed ID: 25390008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of a novel estradiol vaginal ring for relief of menopausal symptoms.
    Speroff L
    Obstet Gynecol; 2003 Oct; 102(4):823-34. PubMed ID: 14551014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of a new transdermal delivery system for estrogen replacement therapy in postmenopausal women.
    Figueroa-Casas PR; Alfonsin A; Arrighi A; Bluvstein G; Del Castillo R; Goldsman T; Inglesi J; Itala J; Novelli J; Monti C
    Maturitas; 1994 Dec; 20(2-3):139-44. PubMed ID: 7715465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose transdermal estradiol for symptomatic perimenopause.
    Shulman LP; Harari D
    Menopause; 2004; 11(1):34-9. PubMed ID: 14716180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effectiveness and tolerance of pulsed estrogen therapy in the treatment of menopausal symptoms. Results of a Polish multicenter study].
    Szamatowicz M
    Ginekol Pol; 2005 Mar; 76(3):245-51. PubMed ID: 16018146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of an estradiol transdermal spray in women with menopausal symptoms: a non-interventional study.
    Hadji P; Schmeißer JO; Peters K; Göckeler-Leopold E
    Climacteric; 2024 Jul; ():1-9. PubMed ID: 39036835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief.
    Panay N; Ylikorkala O; Archer DF; Gut R; Lang E
    Climacteric; 2007 Apr; 10(2):120-31. PubMed ID: 17453860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gabapentin vs. low-dose transdermal estradiol for treating post-menopausal women with moderate to very severe hot flushes.
    Aguirre W; Chedraui P; Mendoza J; Ruilova I
    Gynecol Endocrinol; 2010 May; 26(5):333-7. PubMed ID: 20050764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of ultralow-dose transdermal estradiol on postmenopausal symptoms in women aged 60 to 80 years.
    Diem S; Grady D; Quan J; Vittinghoff E; Wallace R; Hanes V; Ensrud K
    Menopause; 2006; 13(1):130-8. PubMed ID: 16607109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
    Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ
    Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Climacteric syndrome].
    Imthurn B; Maurer-Major E
    Ther Umsch; 2000 Oct; 57(10):595-9. PubMed ID: 11081369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of continuous sequential transdermal estradiol and norethindrone acetate in relieving vasomotor symptoms associated with menopause.
    Notelovitz M; Cassel D; Hille D; Furst KW; Dain MP; VandePol C; Skarinsky D
    Am J Obstet Gynecol; 2000 Jan; 182(1 Pt 1):7-12. PubMed ID: 10649149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of a new 7-day transdermal sequential estradiol/levonorgestrel patch in women.
    von Holst T; Salbach B
    Maturitas; 2002 Mar; 41(3):231-42. PubMed ID: 11886769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrasorb.
    Chiechi LM
    IDrugs; 2004 Sep; 7(9):860-4. PubMed ID: 15470604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of Menorest 50 compared with Estraderm TTS 50 in the treatment of postmenopausal symptoms. A randomized, multicenter, parallel group study.
    Pornel B; Genazzani AR; Costes D; Dain MP; Lelann L; Vandepol C
    Maturitas; 1995 Nov; 22(3):207-18. PubMed ID: 8746878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.